Table 1.

Expression of endocannabinoids in animal models of CINP.

CINP model			Expression of endocannabinoids		Reference
Chemotherapy drug	Animals	CINP symptom	Tissue	Change in endocannabinoid levels relative to control
Cisplatin	Male C3H/HeN mice	Mechanical and heat hyperalgesia	Plantar paw skin	Decrease in AEA but no change in 2-AG	[25]
Cisplatin	Male SD rats	Mechanical and cold allodynia	Lumbar spinal cord	Both 2-AG and AEA increased	[24]
			Dorsal hind paw skin	2-AG decreased but not AEA
Cisplatin	Male C3H/HeN mice	Mechanical hyperalgesia	Plantar paw skin	Both 2-AG and AEA decreased	[26]
			DRGs	Both 2-AG and AEA decreased
			Lumbar spinal cord	Both 2-AG and AEA increased
			Midbrain	No effect on both 2-AG and AEA
Cisplatin	Male C3H/HeJ mice	Mechanical allodynia	Plantar paw skin	Decrease in AEA but no change in 2-AG	[27]

2-AG, 2-arachidonoylglycerol; AEA, N-arachidonoylethanolamine (anandamide); SD, Sprague-Dawley.